LONDON--U.K. drugmaker GlaxoSmithKline PLC (GSK.LN) Monday publicized positive results from a late-stage study of a treatment for pulmonary arterial hypertension, a condition characterized by constriction of the blood vessels in the lungs.

The study of the effects of the ambrisentan and tadalafil drugs, carried out in collaboration with Gilead Sciences Inc. (GILD), showed that the combination therapy worked better than either drug administered on its own.

"The length of time before patients experienced clinical failure was significantly prolonged for those receiving first-line combination compared to monotherapy," GSK said.

The two companies now plan to seek regulatory approval for the combination therapy by submitting the study data to regulators in the U.S., European Union and elsewhere.

At 1309 GMT, GSK shares were down 24 pence or 1.66% at 1,424 pence.

Write to Ed Ballard at ed.ballard@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more GSK Charts.